ID   NYH/VM
AC   CVCL_0B29
SY   OC-NYH/VM
DR   Wikidata; Q54931220
RX   PubMed=8390259;
RX   PubMed=9062409;
CC   Selected for resistance to: ChEBI; CHEBI_75988; Teniposide (VM-26).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8207 ! GLC-2
SX   Male
AG   41Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 19-12-24; Version: 9
//
RX   PubMed=8390259; DOI=10.1016/0006-2952(93)90013-M;
RA   Jensen P.B., Sorensen B.S., Sehested M., Demant E.J.F., Kjeldsen E.,
RA   Friche E., Hansen H.H.;
RT   "Different modes of anthracycline interaction with topoisomerase II.
RT   Separate structures critical for DNA-cleavage, and for overcoming
RT   topoisomerase II-related drug resistance.";
RL   Biochem. Pharmacol. 45:2025-2035(1993).
//
RX   PubMed=9062409; DOI=10.1038/bjc.1997.154; PMCID=PMC2063407;
RA   Jensen P.B., Holm B., Sorensen M., Christensen I.J., Sehested M.;
RT   "In vitro cross-resistance and collateral sensitivity in seven
RT   resistant small-cell lung cancer cell lines: preclinical
RT   identification of suitable drug partners to taxotere, taxol, topotecan
RT   and gemcitabin.";
RL   Br. J. Cancer 75:869-877(1997).
//